Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity
Wei-Wu He, insider at CASI Pharmaceuticals
Wei-Wu He Insider Alerts

Get notified the next time Wei-Wu He buys or sells CASI Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Wei-Wu He Insider Information

Dr. He has been Chairman of the Company since February 2012 and Executive Chairman since February 2018 and Chief Executive Officer since 2019. Prior to joining CASI, Dr. He was the CEO of OriGene Technologies, Inc. and remains Chairman of the Board of Directors. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 60 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 30 research publications and inventor of over 32 issued patents. Dr. He received his Ph.D. in Molecular Biology from Baylor College of Medicine and received an M.B.A. degree from the Wharton School.

What is Wei-Wu He's net worth?

The estimated net worth of Wei-Wu He is at least $4.18 million as of March 26th, 2021. Dr. He owns 4,683,994 shares of CASI Pharmaceuticals stock worth more than $4,180,465 as of November 30th. This net worth estimate does not reflect any other investments that Dr. He may own. Learn More.

What is Wei-Wu He's salary?

As the CEO of CASI Pharmaceuticals, Inc., Dr. He earned a total compensation package of $819,487.00 in 2020. Dr. He earned a salary of $577,656.00, and other compensation of $241,831.00.

How do I contact Wei-Wu He?

The corporate mailing address for Dr. He and other CASI Pharmaceuticals executives is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. CASI Pharmaceuticals can also be reached via phone at (240) 864-2600 and via email at [email protected]

Has Wei-Wu He been buying or selling shares of CASI Pharmaceuticals?

In the last ninety days, Wei-Wu He has bought $198,000.00 in CASI Pharmaceuticals stock. Most recently, on Wednesday, November 17th, Wei-Wu He bought 200,000 shares of CASI Pharmaceuticals stock. The stock was acquired at an average cost of $0.99 per share, with a total value of $198,000.00.

Are insiders buying or selling shares of CASI Pharmaceuticals?

During the last year, CASI Pharmaceuticals insiders bought shares 3 times. They purchased a total of 3,202,000 shares worth more than $6,352,880.00. The most recent insider tranaction occured on November, 17th when CEO Wei-Wu He bought 200,000 shares worth more than $198,000.00. Insiders at CASI Pharmaceuticals own 24.3 % of the company.

Information on this page was last updated on 11/17/2021.

Wei-Wu He Insider Trading History at CASI Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2021Buy200,000$0.99$198,000.00View SEC Filing Icon  
3/26/2021Buy3,000,000$2.05$6,150,000.004,683,994View SEC Filing Icon  
7/22/2020Buy2,952,426$1.90$5,609,609.404,836,523View SEC Filing Icon  
5/20/2020Buy86,265$2.61$225,151.651,827,663View SEC Filing Icon  
5/18/2020Buy438,932$2.05$899,810.601,827,663View SEC Filing Icon  
3/27/2020Buy6,880$2.09$14,379.201,358,900View SEC Filing Icon  
3/25/2020Buy196,398$1.94$381,012.121,023,925View SEC Filing Icon  
3/19/2020Buy234,488$1.57$368,146.16827,527View SEC Filing Icon  
3/17/2020Buy264,192$1.50$396,288.00827,527View SEC Filing Icon  
8/16/2019Buy20,000$3.20$64,000.00827,527View SEC Filing Icon  
8/14/2019Buy160,000$3.17$507,200.00807,527View SEC Filing Icon  
3/19/2018Buy3,086,419$3.24$9,999,997.56847,527View SEC Filing Icon  
10/10/2017Buy100,000$1.95$195,000.00View SEC Filing Icon  
10/6/2017Buy200,000$1.83$366,000.00View SEC Filing Icon  
9/19/2017Buy207,502$1.75$363,128.50513,525View SEC Filing Icon  
9/18/2017Buy173,500$1.75$303,625.00513,525View SEC Filing Icon  
9/15/2017Buy315,327$1.33$419,384.91212,323View SEC Filing Icon  
10/3/2016Buy1,871,605$1.19$2,227,209.9524,698View SEC Filing Icon  
See Full Table

Wei-Wu He Buying and Selling Activity at CASI Pharmaceuticals

This chart shows Wei-Wu He's buying and selling at CASI Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CASI Pharmaceuticals Company Overview

CASI Pharmaceuticals logo
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.
Read More

Today's Range

Now: $0.89
Low: $0.88
High: $0.95

50 Day Range

MA: $1.10
Low: $0.89
High: $1.26

2 Week Range

Now: $0.89
Low: $0.87
High: $3.90

Volume

1,498,493 shs

Average Volume

1,664,321 shs

Market Capitalization

$124.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.33
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity